Previous article![]( "Top 25 Indian Pharma Companies by Revenues in 2024")
Next article![]( "India’s Medical Devices Market: Strategic Implications and Key Investors")
Monday, April 20, 2026
34.7
C
Bengaluru
Hot topics
Aflibercept: When Originators Stop Fighting and Start Licensing
When Regeneron Pharmaceuticals and Bayer AG signed a licensing...
What about Indian Pharma?
Articles by K. Hariram, Vivek Hattangadi, Soham Wagh, Dr. Rajshri Jobanputra, and Rashesh Patel
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
Indian Pharma Power 23
By MedicinMan Editorial Team
India’s pharmaceutical dominance doesn’t rest on...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune
In the pharmaceutical world, we often focus on the...
A Tale of Two Companies – Sun Pharma’s Odyssey and Organon’s Second Act
Sun Pharma’s Odyssey and Organon’s Second Act – And...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune
In the pharmaceutical world, we often focus on the...
A Tale of Two Companies – Sun Pharma’s Odyssey and Organon’s Second Act
Sun Pharma’s Odyssey and Organon’s Second Act – And...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune
In the pharmaceutical world, we often focus on the...
A Tale of Two Companies – Sun Pharma’s Odyssey and Organon’s Second Act
Sun Pharma’s Odyssey and Organon’s Second Act – And...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune
In the pharmaceutical world, we often focus on the...
A Tale of Two Companies – Sun Pharma’s Odyssey and Organon’s Second Act
Sun Pharma’s Odyssey and Organon’s Second Act – And...
Hot topics
Customer Acquisition Cost (CAC) & Indian Pharma
Introduction
Customer Acquisition Cost (CAC) is a key metric representing...
First Approach in Pharma
Independence Day Special issue with Vivek Hattangadi tracing the India pharma brand story from before Independence till today.
Digital Noise to Digital Voice – A 4-Module Workshop for Pharma People
https://www.youtube.com/watch?v=BOO_CNxEzwQ
When Covid19 struck for the first time in March 2020, the...
Creador Bets Big on Indian Pharma with 7% La Renon Stake
In a significant development for the Indian pharmaceutical industry,...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune
In the pharmaceutical world, we often focus on the...
A Tale of Two Companies – Sun Pharma’s Odyssey and Organon’s Second Act
Sun Pharma’s Odyssey and Organon’s Second Act – And...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune
In the pharmaceutical world, we often focus on the...
A Tale of Two Companies – Sun Pharma’s Odyssey and Organon’s Second Act
Sun Pharma’s Odyssey and Organon’s Second Act – And...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune
In the pharmaceutical world, we often focus on the...
A Tale of Two Companies – Sun Pharma’s Odyssey and Organon’s Second Act
Sun Pharma’s Odyssey and Organon’s Second Act – And...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune
In the pharmaceutical world, we often focus on the...
A Tale of Two Companies – Sun Pharma’s Odyssey and Organon’s Second Act
Sun Pharma’s Odyssey and Organon’s Second Act – And...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
Ritesh Desai has joined Standard Chartered India as Executive...
The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation
The story of Healthium is not just one of...
The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune
In the pharmaceutical world, we often focus on the...
Newsletter
Get important news delivered directly to your inbox and stay connected!